Panorama® SMART Study Confirms Market-Leading Performance in Largest Prospective NIPT Trial to DatePRNewsWire • 02/03/21
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ TestingPRNewsWire • 01/14/21
Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/21
U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA PatentPRNewsWire • 12/18/20
Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all PregnanciesPRNewsWire • 12/01/20
New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer PatientsPRNewsWire • 11/30/20
Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment MonitoringPRNewsWire • 11/10/20
Natera, Inc. (NTRA) CEO Steve Chapman on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin PregnanciesPRNewsWire • 10/30/20
Natera's Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million LivesPRNewsWire • 10/08/20
Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness ChallengePRNewsWire • 10/05/20
Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™PRNewsWire • 10/02/20
